USPTO serial 79255127
FREELINE
Reviewed by CopyMark Law Group
Reg. 5999142Status 404
- Filing date
- Status date
- Registration date
- Mar 3, 2020
- Examiner
- BUCHANAN WILL, NORA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with FREELINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Samantha M. Quimby
Samantha M. Quimby Frost Brown Todd LLC3300 Great American Twr., 301 E. 4th St.Cincinnati, OH 45202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Freeline Therapeutics Limited
- Other trademarks owned by Freeline Therapeutics Limited
- Other trademarks owned by Freeline Therapeutics Limited
- Other trademarks in Class 005
- Similar marks named FREELINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 20, 2026 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Aug 20, 2026 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Mar 3, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 6, 2023 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 15, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 24, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 8, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 8, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 3, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 3, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 17, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 17, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 27, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 12, 2019 | ALIE | ASSIGNED TO LIE | — |
| Nov 7, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 6, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 6, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 6, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 14, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 8, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 7, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 17, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 16, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 27, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 27, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 25, 2019 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Mar 21, 2019 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |